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Glycodiversification, an invaluable tool for generating
biochemical diversity, can be catalyzed by glycosyl-
transferases, which attach activated sugar ‘‘donors’’
onto ‘‘acceptor’’ molecules. However, many glyco-
syltransferases can tolerate only minor modifications
to their native substrates, thus making them unsuit-
able tools for current glycodiversification strategies.
Here we report the production of functional chimeric
glycosyltransferases by mixing and matching the
N- and C-terminal domains of glycopeptide glycosyl-
transferases. Using this method we have generated
hybrid glycopeptides and have demonstrated that
domain swapping can result in a predictable switch
of substrate specificity, illustrating that N- and
C-terminal domains predominantly dictate acceptor
and donor specificity, respectively. The determina-
tion of the structure of a chimera in complex with
a sugar donor analog shows that almost all sugar-
glycosyltransferase binding interactions occur in the
C-terminal domain.
INTRODUCTION
The presence of carbohydrate appendages is often crucial for
bioactive natural products to function properly (Varki et al.,
1999). Glycosyltransferases (GTs) thus represent a significant
class of enzyme, catalyzing the attachment of activated sugar
‘‘donors’’ onto ‘‘acceptor’’ molecules, and glycodiversification
is an invaluable tool for generating biochemical diversity (Thibo-
deaux et al., 2007; Salas and Mendez, 2007) The engineering of
bioactive natural product biosynthetic pathways represents an
attractive option to generate analogs that possess superior
medicinal properties. Examples of engineered glycodiversifica-
tion strategies include gene disruption of the TDP-desosamine
pathway inS. venezuelae to generatenovel analogsof pikromycin
(Borisova et al., 1999), using the reversibility of GTs to exchange
sugars between natural products (Minami et al., 2005; Zhang
et al., 2006), and the introduction of deoxysugar biosynthesis
plasmids into natural product producers (Perez et al., 2006;
Schell et al., 2008).
These strategies rely on the native GT possessing relaxed
substrate specificity toward the sugar donor, the aglycone676 Chemistry & Biology 16, 676–685, June 26, 2009 ª2009 Elsevieracceptor, or both, yet many GTs cannot tolerate anything
more than minor modifications to their native substrates. Such
high specificity makes many GTs unsuited to current glycodiver-
sification strategies, significantly reducing their applicability.
Examples include GtfA, Orf1, and Orf10*, GTs involved in the
biosynthesis of the glycopeptides chloroeremomycin (Lu et al.,
2004), and teicoplanin (Li et al., 2004; Howard-Jones et al.,
2007). However, thus far, few unnatural GT-B GTs have been
constructed with the aim of altering substrate specificity; notable
examples include GTs involved in the biosynthesis of urdamycin
(Hoffmeister et al., 2001, 2002) and the directed evolution of
a macrolide GT (Williams et al., 2007).
Glycopeptides are clinically indispensable antibiotics that are
decorated with a variety of sugars. The sugars that decorate
glycopeptides can increase antibacterial activity by enhancing
membrane localization (Beauregard et al., 1995), can aid in glyco-
peptide dimerization (Mackay et al., 1994), and have even been
postulated to be antibacterial without the attached peptide
(Ge et al., 1999). All glycopeptide GTs that use nucleotide
diphospho-sugar (NDP-sugar) donors belong to the GT-B struc-
tural superfamily. The GT-B fold is characterized by a bilobal
architecture, with two Rossmann-like ab domains facing each
other. It is believed that the N-terminal domain contains the
acceptor site and theC-terminal domain contains theNDP-sugar
donor site; catalysis occurs at the interface of these domains
(Coutinho et al., 2003). Structurally characterized examples of
this structural superfamily include MurG (Hu et al., 2003), DNA
b-glucosyltransferase (Vrielink et al., 1994), and OleD (Bolam
et al., 2007). An analysis of the CAZy (carbohydrate-active
enzymes) database reveals that over 19,000 sequenced GTs
are predicted to adopt this fold.
Domain swapping is a common engineering strategy for
biological systems that have distinct substrate binding and cata-
lytic or regulatory regions, yet GT domain swapping is relatively
unexplored. A few GT domain swapping examples have been
reported, including moving the C domains between UDP-gluco-
syltransferases (Cartwright et al., 2008) and chimeras of 91%
identical urdamycin GTs (Hoffmeister et al., 2001, 2002). An early
domain swapping study by Mackenzie (1990) identified that the
N domain of rat UDP-glucuronyltransferases is responsible for
acceptor binding. In our study we report on the generation and
characterization of three chimeric glycopeptide GTs and show
that N- and C-terminal domains predominantly dictate acceptor
and donor specificity, respectively. Activity analyses reveal these
chimeras topossessactivities comparable to their parents.Using
X-ray crystallography we have solved the structure of GtfAH1,Ltd All rights reserved
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Chimeric Glycopeptide GlycosyltransferasesFigure 1. Mixing and Matching GT-B Donor and Acceptor Domains
(A) A schematic of the concept applied to the glycopeptide GTs GtfB and Orf10*. GtfB (Mulichak et al., 2001; PDB 1IIR) and Orf10* structure (predicted using the
Phyre fold recognition server [Bennett-Lovsey et al., 2008]). Figures were generated using PyMOL.
(B) Fusion sites used for construction of chimeric GTs; 10% SDS-PAGE: M, protein ladder; 1, GtfBH1; 2, GtfBH2; 3, GtfAH1.a remarkably active and promiscuous chimeric GT, to 1.15 A˚
resolution in complex with UDP and to 1.30 A˚ resolution in
complex with UDP-2-deoxy-2-fluoro-glucose. This shows that
almost all sugar-GT binding interactions occur in the C-terminal
domain for glycopeptide GTs. Taken together, these results
demonstrate the viability of generating highly active chimeric
GTs with novel and predictable activities.
RESULTS
Design and Construction of GtfB Chimeras
The presence of two distinct substrate binding domains makes
chimeric GT-B GTs an attractive bioengineering target, and
the glycopeptide GTs GtfB and Orf10* were used to assess the
feasibility of functional chimeric GTs. These GTs are responsible
for transferring glucose (Glc) and N-acetylglucosamine (GlcNAc)
to 4-OH-PheGly4 of the vancomycin and teicoplanin aglycones
(AGV and AGT), respectively (Figure 1A) (Li et al., 2004; Mulichak
et al., 2001). Orf10* and GtfB possess significant sequence simi-
larity (70% identity) and perform analogous glycosylations, yet
nevertheless act on different donor and acceptor substrates.
Success with such a model system would indicate the feasibility
of generating functional chimeric GTs by fusing heterologous
donor and acceptor domains.
The linker region for GtfB and Orf10* has been approximately
defined as amino acids 219–227 (random coil region) and 228–
235 (C-terminal linking a helix). Gln206 was chosen as the fusion
site as it corresponds to a common PstI restriction site in both
genes (Figure 1B). Although this residue precedes the linker
region, there is very high similarity between GtfB and Orf10*
within this region (90.5% identity from aa 206–226), so it was
anticipated that this sitewould not disrupt theN-terminal domain.
Expression constructs were created by digesting gtfB-pET28a
and orf10*-pET28a with PstI and MluI then heterologously
re-ligating the resulting fragments. GtfBH1 (N-terminal GtfB,
C-terminal Orf10*) and GtfBH2 (N-terminal Orf10*, C-terminal
GtfB) were then expressed in E. coli BL21(DE3) with N-terminalChemistry & Biology 16,hexahistidine tags and subjected to in vitro analysis of their reac-
tivity and specificity.
Both chimeraswere expressed as soluble proteins (Figure 1B),
and protein identity was confirmed by liquid chromatography/
electrospray ionization tandem mass spectrometry (LC-ESI-
MS): GtfBH1 observed mass = 44,493 Da (predicted mass for
GtfBH1 after loss of N-formyl-methionine = 44,498 Da); GtfBH2
observed mass = 44,577 Da (predicted mass for GtfBH2 after
loss of N-formyl-methionine = 44,584 Da). The solubility of these
proteins indicates that the domain swap does not result in severe
protein misfolding, although expression yields appear to be
related to the yield of the GT that provides the N terminus (puri-
fied protein yields from parallel 1 liter cultures: GtfB = 7.6 mg;
Orf10* = 1.6 mg; GtfBH1 = 4.6 mg; GtfBH2 = 1.0 mg).
Analysis of GtfB Chimera Activity and Specificity
GtfBH1 and GtfBH2 were tested for GT activity with AGT,
AGV, uridine diphospho-glucose (UDP-Glc), and UDP-GlcNAc
(Table 1). We also used competitive assays to probe donor spec-
ificity by incubating equimolar amounts of UDP-GlcNAc and
UDP-Glc with the appropriate aglycone and GT. The reaction
turnover rates of the chimericGTs indicate that their catalytic effi-
ciencies are comparable to their parent GTs. Furthermore, the
relative rates of the GTs with AGV and AGT demonstrate that
theN-terminal domain entirely controls acceptor binding. Hence,
the acceptor specificities of GtfBH1 and GtfBH2 correspond
to the specificities of GtfB and Orf10*, respectively. GtfBH1 and
GtfB can glycosylate both AGV and AGT, whereas Orf10* and
GtfBH2 can only transfer sugars to AGT. The data also shows
that the C-terminal domain predominantly controls sugar speci-
ficity, although its control is not as absolute as in the case of
the N-terminal domain. GtfBH1 has the C domain of Orf10* but
it does not possess the same high selectivity for UDP-GlcNAc
as Orf10*. Competitive assays indicate that Orf10* and GtfB
both have a >100-fold preference for their preferred sugar, while
GtfBH1 only has a 1.48-fold preference for GlcNAc over Glc. In
contrast, the sugar specificity of GtfBH2 is comparable to the676–685, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 677
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Chimeric Glycopeptide GlycosyltransferasesTable 1. Activity of Hybrid GtfB-like Proteins in Comparison to Parent GTs
GT
AGT AGV Competitive Assays
UDP-GlcNAc UDP-Glc UDP-GlcNAc UDP-Glc GlcNAc/Glc ratio AGV/AGT ratio
Orf10* 1.000 0.575 - - 130:1 -
GtfB - 0.080 0.039 0.803 0.006:1 5.1:1
GtfBH1 0.004 - 0.141 0.122 1.48:1 15.1:1
GtfBH2 0.003 0.578 - - 0.014:1 -
Relative activities are normalized to Orf10* activity with AGT and UDP-GlcNAc (4.93 mMper hour per micromole of enzyme). A dash denotes no activity
detected by LC-ESI-MS analysis. All enzymes were tested at 20C with 1 mM acceptor and 2 mM donor and all data are the average of three exper-
iments. Numbers in bold reflect both the maximal activity for the enzyme and the particular set of substrates used.specificity ofGtfBandGtfBH2canonly transferGlcNAc toAGTat
a highly reduced rate. Hence the C-terminal domain appears to
be the strongest determinant of sugar specificity but additional
regions are also influential. The different specificities of the
chimeras may indicate that there is a GtfB N-domain interaction
with glucose but no Orf10* N-domain interaction with N-acetyl-
glucosamine.
Design and Construction of GtfA Chimeras
The creation of two functional hybrids fromOrf10* andGtfB acted
as a promising proof of principle for the mixing and matching of
GT-B domains to create GTs with novel and predictable activity.
This initial success encouraged us to apply domain swapping to
amore functionally disparate pair ofGTs. Amuch less glycodiver-
sified site is the benzylic hydroxyl group of b-OH-Tyr6. GtfA and
Orf1 transfer epi-vancosamine and N-acetylglucosamine onto
this position on desvancosaminyl vancomycin (DVV) and teico-
planin glucosaminyl-pseudoaglycone 1, respectively (Figure 2A;
Lu et al., 2004; Li et al., 2004). As with GtfB/Orf10*, these two
proteins possess significant similarity (66% identity). Crucially,
GtfA and Orf1 use very different sugar donors and are very
specific toward their native substrates, so no cross-reactivity
exists. A consequence of this specificity is that few glycopeptideanalogs have been produced by glycodiversification at b-OH-
Tyr6. TDP-L-b-4-epi-vancosamine is an L-trideoxyhexose which
has different substituents at every position around the ring
compared to UDP-D-a-4-N-acetylglucosamine. In addition,
GlcNAc is attached tob-OH-Tyr6byab linkage,whereasepi-van-
cosamine is attached via an a linkage. With such differences,
a rational site-directed mutagenesis approach is unlikely to
switch specificity.
pET28a(+) plasmids containing the chimeric genes were con-
structed in an analogous fashion to the GtfB chimeras. Trp201
was chosen as the fusion site for the GtfA-Orf1 chimeras. This
residue is at the beginning of the unstructured random coil region
that links the two substrate-binding domains and corresponds
to a common BamHI site in the two genes. One factor that
was not assessed for the GtfB chimeras is the effect, if any, of
the site of the His6-tag, so constructs were generated for both
N- and C- terminally His6-tagged chimeras. GtfAH1 (N-terminal
GtfA, C-terminal Orf1) was expressed in E. coli BL21(DE3) as
a hexahisitidine tagged protein. The GtfAH2 hybrid (N-terminal
Orf1, C-terminal GtfA) was also expressed as a soluble protein
but its activity could not be investigated due to TDP-epi-vancos-
amine unavailability (GtfAH2 is not functional with glucose-like
sugar donors).Figure 2. GtfA-Orf1 Domain Swapping
(A) Native activity of GTs Orf1 and GtfA.
(B) Hybrid vancomycin derivatives produced by GtfAH1, a chimera generated by a fusion of the N-terminal domain of GtfA with the C-terminal domain of Orf1.
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Figure 3. Three-Dimensional Plots of Initial Reaction Velocities of GtfAH1 with Acceptor Glycopeptides and UDP-GlcNAc
All points represent the average of three experiments. The white surface mesh shows the nonlinear curve fitting parameters fitted to this data using Origin 7.
(A) DVV as acceptor.
(B) AGV as acceptor.
(C) Vancomycin as acceptor.
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GtfAH1 was assayed with AGV, DVV, AGT, vancomycin, and
N-acetylglucosaminyl-AGV 2 as acceptor molecules and UDP-
GlcNAc/Glc as sugar donors. Remarkably, activity was observed
with all substrate combinations (Figure 2B). The position of the
GtfAH1 His6 tag did not affect enzymatic activity. The ability of
GtfAH1 to glycosylate all these glycopeptide acceptors (see
Figure S1 available online for examples of its activity) is highly
unexpected, given the very strict substrate specificity of
its parent GTs. Wild-type GtfA possesses only trace activity
with AGV or vancomycin (Lu et al., 2004), thus implying strict
N-domain specificity, while we detected no activity when Orf1
was tested with UDP-glucose and AGT or 1. GtfAH1 donor spec-
ificity between UDP-Glc and UDP-GlcNAc was assessed using
competitive assays, which showed that GtfAH1 only exhibits
a 2.2-fold preference for N-acetylglucosamine over glucose,
regardless of the acceptor molecule (Figure S2). Therefore,
domain swapping appears to have significantly loosened
substrate specificity.Kinetic Analysis of GtfAH1
The broad specificity of GtfAH1 clearly demonstrates the poten-
tial of hybrid GTs to generate previously difficult to access
natural product derivatives. To probe the biosynthetic value of
GtfAH1 we determined its two-substrate kinetic parameters
with UDP-GlcNAc and DVV/AGV/vancomycin. A two-substrate
kinetic analysis generates two binding constants per substrate
(KiA and KmA), where KmA is the Michaelis constant for substrate
A. The true meaning of KiA depends on whether the substrates
bind in an ordered or random manner (Cornish-Bowden, 2004).
If substrate A binds first in an ordered mechanism, KiA is the
disassociation constant for the enzymeA complex. To determine
a full set of kinetic parameters, initial rates were required for a
range of both substrate concentrations.
Kinetic parameters were obtained by nonlinear curve fitting
using Origin 7 (Figure 3 and Table 2). A comparison with the
parameters reported by the Walsh group for GtfA (Lu et al.,
2004) and Orf1 (Howard-Jones et al., 2007) shows that GtfAH1
is a highly active chimera that has a surprisingly high affinityTable 2. Two-Substrate Kinetic Parameters for GtfAH1 with UDP-GlcNAc and Glycopeptide Acceptor Substrates
Glycopeptide Substrate
Acceptor Parameters UDP-GlcNAc Parameters
GtfAH1 GtfAa GtfAH1 Orf1b
DVV kcat/min
1 6.20 ± 0.77 2.3 ± 0.5 6.22 ± 0.76 7.6 ± 0.1
Km/mM 0.51 ± 0.15 107 1398 ± 284 32 ± 6
Ki/mM 0.30 ± 0.06 ND 827 ± 229 ND
AGV kcat/min
1 1.64 ± 0.14 <0.05 1.64 ± 0.14 0.38 ± 0.01c
Km/mM 2.84 ± 0.53 ND 1166 ± 216 807 ± 66
c
Ki/mM 0.84 ± 0.45 ND 347 ± 190 ND
Vancomycin kcat/min
1 1.80 ± 0.05 <0.05d 1.80 ± 0.05 NA
Km/mM 352 ± 49 ND 6960 ± 2451 NA
Ki/mM 30.7 ± 9.5 ND 609 ± 246 NA
Errors quoted represent the standard error of curve fitting. ND, not determined.
a Parameters obtained from Lu et al. (2004).
b Parameters obtained from Howard-Jones et al. (2007).
c Data refer to Orf1 donor parameters with AGT (Howard-Jones et al., 2007).
d kcat is quoted for GtfA activity with epivancomycin (Lu et al., 2004).
Chemistry & Biology 16, 676–685, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 679
Chemistry & Biology
Chimeric Glycopeptide Glycosyltransferasestoward DVV and AGV when compared to the DVV:GtfA and
Orf1:1 Km values (0.51 mM and 2.84 mM versus 107 mM and
85 mM, respectively). Additionally, the Km of vancomycin with
GtfAH1 (352 mM) is comparable to the parent GT Km values listed
above, while all kcat values are of a similar magnitude to the wild-
type activities of GtfA and Orf1.
Although substrate specificity has been broadened, there
is still a definite trend regarding the relative activity of GtfAH1
with DVV, AGV, and vancomycin. The Km and Ki increase in the
order DVV < AGV < vancomycin, whereas kcat decreases in
the order DVV > AGV z vancomycin. This evidently reflects an
N domain that is optimized to bind DVV and is least capable in
accommodating the additional steric bulk of vancomycin. Inhibi-
tion studies are usually used to determine whether a mechanism
proceeds via a random or an ordered mechanism. However,
a study by Yang et al. (2005) indicated that, for GTs, a ratio of
KmA/KmB greater than ten strongly implies an ordered mecha-
nism. A Km(UDP-GlcNAc)/Km(DVV) ratio of 2741 indicates that
DVV binds first as part of an ordered mechanism in GtfAH1.
Isothermal titration calorimetry was used to verify the low-
micromolar affinity between GtfAH1 and DVV. This provides a
dissociation constant (KD) that should be a similar magnitude
to Km and Ki. C- and N-terminally His6-tagged GtfAH1 were
analyzed, along with C-terminally His6-tagged GtfA (Figure S3).
This analysis reinforced the data obtained by kinetic analysis
as the KD for DVV with GtfAH1 was determined to be 2.26 mM.
Along with the kinetic data, this tight binding is the clearest
indication yet that GT domain swapping can generate biosyn-
thetically relevant enzymes. Interestingly, the KD of DVV with
GtfA is over twenty times stronger than the kinetically deter-
mined Km (4.85 mM compared to 107 mM; Lu et al., 2004). The
basis for this difference has not been elucidated, although may
be a simple difference in protein preparation and/or its subse-
quent stability. Alternatively, it may be the difference in GtfA-
DVV affinity depending on whether TDP-epi-vancosamine is
bound to the enzyme or not.
Figure 4. Structural Analysis of GtfAH1
(A) 1.15 A˚ resolution structure of GtfAH1 contain-
ing bound UDP (gray) with GtfA N-terminal domain
colored green andOrf1 C-terminal domain colored
purple.
(B) 2Fo  2Fc electron density map of the uracil
ring of UDP sandwiched between His278 and the
Glu275-Arg11 salt bridge. The electron density
for UDP, His278, Glu275, and water molecules
present in the UDP binding site is illustrated.
Structural Analysis of GtfAH1
The activity and promiscuity of GtfAH1
demonstrates that domain swapping
can not only provide novel GT activity,
but can also broaden substrate tolerance
while improving catalytic efficiency. To
analyze the structural determinants that
control specificity and activity we deter-
mined the crystal structure of C-termi-
nally His6-tagged GtfAH1 to 1.15 A˚
resolution, the highest achieved for a
GT-B fold GT (Figure 4A). Statistics for data collection and refine-
ment are listed in Table 3. GtfAH1 possesses characteristic GT-B
bilobal architecture, with two facing Rossmann-like ab domains
and contains UDP in the C-domain nucleotide binding site, either
acquired prior to purification or by hydrolysis of co-crystallized
UDP-GlcNAc. The uracil ring is sandwiched between an Arg11-
Glu275 ion pair and potential pi stacking with His278 (Figure 4B).
Comparison with the open and closed structural conformations
of GtfA (Mulichak et al., 2003) suggests that loop 256–270
swings to allow for a hydrophobic interaction between the side
chain of Trp258 and loops 57–60 (VRAG) and 229–231 (GSG),
indicating that the GtfAH1:UDP complex exists in the closed
conformation, as would be expected. A structural superposition
of GtfA and GtfAH1 shows that Trp258 occupies an almost iden-
tical position to Trp260 in GtfA (Figure S4A).
These trans-domain interactions are fully analogous to those
that occur in the wild-type GtfA:TDP complex; the ability of
GtfAH1 to adopt this conformation illustrates that such structural
subtleties can be retained in a chimera. However, the presence of
these trans-domain interactions may complicate the generation
of future chimeras, especially between more distantly related
GTs. To investigate the regularity of a trans-domain Arg-Glu
salt bridge to cap the pyrimidine ring, a sequence alignment
was performed across 136 GT-B bacterial natural product GTs
(Figure S5). This shows that the salt bridge is confined to the
glycopeptide GTs, the putative rifampin GT Rgt (NCBI accession
number AAK84835), and the mycinamicin GT MycD (Anzai et al.,
2003). The majority of GTs appear to use a C-terminal aromatic
residue that aromatically caps the pyrimidine ring (61% of
sequences analyzed). This mechanism is observed in the struc-
tures of OleD (Bolam et al., 2007), VvGT1 (Offen et al., 2006),
andMurG (Hu et al., 2003). The trans-domain tryptophan interac-
tion also appears to be confined to the glycopeptide GTs (data
not shown).
The structures of the N-terminal domains of GtfA and GtfAH1
are almost identical (aa 1–200; backbone rmsd = 0.355 A˚), while
680 Chemistry & Biology 16, 676–685, June 26, 2009 ª2009 Elsevier Ltd All rights reserved
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GtfAH1:UDP GtfAH1:UDP-2F-Glc
Data collection statistics
Space group C2221 C2221
Cell parameters (A˚) a = 111.1, b = 129.7, c = 67.1 a = 111.5, b = 129.8, c = 67.4
Wavelength (A˚) 0.977 0.98
Resolution range (A˚) (outer shell) 42.80–1.15 (1.21–1.15) 29.92–1.30 (1.37–1.30)
No. of total reflections (outer shell) 115,4832 (130,919) 838,486 (121,662)
No. of unique reflections (outer shell) 169,485 (23,415) 119,259 (17,259)
Multiplicity (outer shell) 6.8 (5.6) 7.0 (7.0)
Rmerge (%) (outer shell) 7.7 (64.7) 7.4 (56.9)
Completeness (%) (outer shell) 99.2 (94.7) 99.9 (100)
Refinement statistics
Resolution range (A˚) 42.80–1.15 29.25–1.30
Rcryst (%)
a 17.1 16.4
Rfree (%)
b 18.5 18.4
No. of reflections 160,958 113,256
No. of protein residues 383 392
No. of water molecules 608 630
No. of phosphates 4 2
Ligand molecules 1 UDP 1 UDP-2F-Glc
Average Bfactor (A˚
2)
Protein (main, side, and whole chain) 9.4, 10.9, 10.1 10.6, 17.6, 14.5
Phosphate 29.1 40.2
UDP or UDP-2F-Glc 7.9 14.8
Water 26.4 28.8
PDB code 3H4T 3H4I
aRcryst = SkFobsj  jFcalck/SjFobsj, where Fobs and Fcalc are the observed and calculated structure factor amplitudes.
bRfree = Rfactor for 5% of the data that were not included during crystallographic refinement.their C-terminal domains are highly similar despite significant
differences in sequences and sugar specificities (aa 218–389;
sequence identity = 65%; backbone rmsd = 0.703 A˚). The most
significant structural difference between the two proteins, and
a possible rationale for increased acceptor promiscuity, is the
318NVVE321 loop that is present in GtfA but not in GtfAH1. This
loophasbeenproposed to act in a trans-domainmanner to assist
in DVV binding (Mulichak et al., 2003), although the structure
of GtfAH1 indicates the contrary. Without this loop, the turn
between Cb5 and Ca5 (GtfAH1 aa 312–315) is now within
H-bonding distance of DVV. In particular, Lys313 is well posi-
tioned to H bond with the C terminus of DVV (Figure S4B). Such
additional interactions may explain this chimera’s enhanced
affinity toward DVV.
GtfAH1 Complex with UDP-2-deoxy-2-fluoro-glucose
Owing to the weak natural hydrolytic activity of GtfAH1, we
were unable to obtain the crystal structure of a co-complex
with UDP-GlcNAc. Sugar recognition in glycopeptide GTs is
poorly understood, especially as the sugars utilized can differ
considerably, and a structure with an intact NDP-sugar would
structurally rationalize the observed switch in sugar specificities
seen with the GT chimeras.
We therefore co-crystallized GtfAH1 with UDP-2-deoxy-2-
fluoro-glucose (UDP-2F-Glc; Gordon et al., 2006). The highlyChemistry & Biology 16,electronegative 2-fluoro group withdraws electron density from
the anomeric carbon where glycosyltransfer occurs. This effect
is sufficient to render the molecule unreactive toward glycosyl-
transfer or hydrolysis, thus making it an excellent GT inhibitor.
A structure of GtfAH1 in complex with UDP-2F-Glc at a 1.30 A˚
resolution was obtained (see Figure S6 for a numbered stereo
view), where the electron density for UDP-2F-Glc is clearly
visible in a position expected for UDP-GlcNAc (Figure 5A). A
comparison with the GtfAH1:UDP complex shows that there is
very little structural reorganization after the sugar is transferred
to an acceptor molecule (backbone rmsd = 0.097 A˚). Despite
the surprisingly low Ki and Km for DVV with GtfAH1, it was not
possible to obtain a co-complex including DVV, possibly due
to unfavorable crystal packing when a glycopeptide is bound.
As expected, there is a network of H bonds between the sugar
and the C-terminal domain (Figure 5B). These include H bonds
between the side chain of Asp315 with O3 and O4 of UDP-2F-
Glc (2.51 A˚ and 3.68 A˚, respectively) and between the Gln316
side chain with O3 and/or F2 (Gln316 may function as an H bond
acceptor/donor with the 2-NAc moiety of GlcNAc). The array of
interactions that this DQ motif makes suggests it has a key role
in glucose binding. Additionally, the backbone amide of Ala294
H bonds with O4.
Asp13, a putative base for catalysis, is 3.54 A˚ from the likely
position of the DVV hydroxyl, based on a structural superposition676–685, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 681
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Residues in the GtfAH1:UDP-2F-Glc Com-
plex
(A) 2Fo  2Fc electron density of UDP-2F-Glc and
interacting GtfAH1 residues at 1.30 A˚ resolution.
(B) Significant active site residues and fitted DVV
structure (fitted from N-terminal structural super-
position with GtfA:DVV complex; PDB code 1PN3).
(C) Schematic of GtfAH1 active site H-bonding
network.with the GtfA:DVV structure, and is also within H-bonding
distance (2.79 A˚) of O6 of UDP-2F-Glc. The distance from the
DVV nucleophilic hydroxyl to the anomeric carbon is 3.62 A˚, so
it is likely that a small degree of structural reorganization is
required to adopt a reactive conformation. Ser10, another
possible active site base (Mulichak et al., 2003), forms an H
bond with the sugar ring oxygen (2.54 A˚). His291 is 3.68 A˚
away from the leaving group oxygen on UDP, so it could possibly
stabilize the charge generated. Ser230 (side chain and main
chain) and Gly12 both H bond with the UDP phosphate
groups. With the exception of residues 10–13, which are highly
conserved across the GT-B superfamily, no N-terminal residues
interact with the sugar. This supports the hypothesis that the
C-terminal domain dictates sugar binding affinity, at least for
glycopeptide GTs.
Owing to the number of important interactions it makes, it
appears possible that the DQmotif could be an important deter-
minant for selecting glucose-like donor sugars. This observation
is supported by structures of UDP-Glc and UDP-2F-Glc with the
plant GTs UGT71G1 (Shao et al., 2005) and VvGT1 (Offen et al.,
2006): both use the DQ motif to bind glucose in an analogous
manner to GtfAH1. A structural alignment with VvGT1 (Figure S7)
reveals remarkably high structural similarity in the sugar-binding
region despite massive evolutionary divergence (22% overall
sequence identity).
To investigate whether this motif is a key feature for selecting
glucose-like sugars, 136 bacterial natural product GTs (see
above) were analyzed. Of these, 25 contain a DQ or EQ motif in
the correct region (Figure S8). Despite the structural information
detailed above, many of these GTs do not transfer glucose-like
sugars, indicating that sugar selectivity must be determined by
additional interactions in these cases. For example, the residues
that H bond 2F-Glc in GtfAH1 are conserved throughout all the
glycopeptide GTs, even those that use vancosamine-like donors
(Figure S9). A structural superposition of GtfD, GtfA, and GtfAH1
shows that most of these residues are structurally conserved.
The exception is D315 and Q316, which are disrupted by the
318NVVE321 insertion in GtfA. However, the DQ motif is undis-
turbed in GtfD (Mulichak et al., 2004), so almost completely
superimposes with the analogous GtfAH1 residues (data not
shown). Elsewhere, there are a few regions that may facilitate
the discrimination between glucose and vancosamine-like
substrates. The six residues following Ser230 are highly variable
between glycopeptide GT subgroups (those that use glucose-
like donors and those that utilize vancosamine-like donors),
including a two amino acid insertion in the vancosaminyltrans-682 Chemistry & Biology 16, 676–685, June 26, 2009 ª2009 Elsevieferases. The three residues before Asp315 also appear to signif-
icantly differ between groups.
The existence of less obvious interactions is supported by
directed evolution studies from Thorson and colleagues (Wil-
liams et al., 2007, 2008). These indicate that substrate specificity
and selectivity, as well as catalytic activity, can be influenced
by residues remote from the expected substrate binding sites.
Site-directed mutagenesis and further structural and activity
analyses will be required to fully dissect the structural basis for
precise sugar selectivity.
DISCUSSION
This study demonstrates the viability of constructing chimeric
GTs to generate novel natural product derivatives and the
method should have wide applicability, given the ubiquity of
GT-B fold GTs. The generality of GT domain swapping is sup-
ported by recent studies by the groups of Bowles (Brazier-Hicks
et al., 2007; Cartwright et al., 2008), Kim (Park et al., 2009), and
Bechthold (Krauth et al., 2009), who have reported interesting
examples of functional chimeric GTs (plant flavanoid, bacterial
aminoglycoside-glycopeptide, and bacterial angucycline GTs,
respectively). All show that the N-terminal domain is responsible
for acceptor binding specificity.
Our study expands the method by creating highly functional
chimeraswith novel substrate specificity; thoseprevious studies,
along with a study on UDP-glucuronyltransferases (Mackenzie,
1990), did not attempt to modify sugar specificity and therefore
the effect of the C-terminal domain on sugar selectivity could
not be established. Chimeras of 91% identical urdamycin GTs
possess novel activities (Hoffmeister et al., 2001), but this activity
was difficult to predict as the C domains of these GTs are almost
identical despite using different sugars. This is very unusual for
GT-B fold GTs and may mark these as atypical GTs.
Our functional and structural analysis of chimera selectivity
clearly identifies acceptor and donor binding sites for the glyco-
peptide GTs, although sugar binding appears to be appreciably
affected by the N-terminal domain. Current evidence on GT-B
trans-domain binding of the sugar residue is conflicting. The
chimeric urdamycin GTs revealed N-terminal domain residues
that control sugar binding (Hoffmeister et al., 2001), and the sugar
specificity of OleD, a macrolide GT, was changed by mutating
residues from the analogous N-domain region in a site-directed
evolution study (Williams et al., 2008). However, in the co-com-
plexes of sugar donors with MurG (Hu et al., 2003), UGT71G1
(Shao et al., 2005), VvGT1 (Offen et al., 2006), and GtfAH1 almostr Ltd All rights reserved
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the exact mode of sugar binding within the GT-B family should
be expected and may account for the differences observed in
GtfBH1 and GtfBH2 specificities, along with the relaxed GtfAH1
UDP-GlcNAc/Glc selectivity.
Nevertheless, these results are clearly encouraging and provide
an indication of the potential that chimeric GTs possess: rational
proteinengineering tocreateGTswithnovel andpredictableactiv-
ities. It will be intriguing to establish the scope of this method with
GTs involved in the biosynthesis of other classes of clinically effi-
cacious natural products. As with domain swapping in proteins
suchaspolyketidesynthases, it is essential thatappropriate fusion
sites are chosen tomaximize the likelihood of a functional chimera
(Kellenberger et al., 2008). The ever expanding GT-B superfamily
structural data set will aid in this process along with the screening
method of Park et al. (2009) for GT activity. Our structural and
sequence analysis implies that trans-domain interactions will
have to be considered when constructing chimeric GTs.
Hybrid GTs should prove particularly useful at derivatizing
natural products whose native GTs possess strict substrate
specificity, perhaps in combination with the C-terminal domain
of GTs, which have proven sugar donor promiscuity. Addition-
ally, this strategy should be amenable to in vivo engineering of
glycosylation pathways; it will be useful to establish whether
the activities and specificities observed in vitro are mirrored
in vivo. Furthermore, the GtfAH1:UDP-2F-Glc crystal structure
should allow for amore surgical approach tomodifying the sugar
specificity of glycopeptide GTs, as well as for GTs that are pre-
dicted to possess analogous sugar-binding regions.
SIGNIFICANCE
Our work demonstrates that the sugar donor specificity of
GTs can be rationally controlled by fully swapping substrate
binding domains. This method has been applied to generate
vancomycin analogs that would be difficult to obtain using
existing glycodiversification techniques. In conjunction
with work performed by the groups of Bechthold (Krauth
et al., 2009), Bowles (Cartwright et al., 2008), and Kim (Park
et al., 2009), a picture is emerging that domain swapping is
a viable strategy for generating highly active unnatural
GTs. The kinetic characterization of GtfAH1 and the activity
analysis of GtfBH1 and GtfBH2 show that domain swapping
does not severely impair catalytic activity and can actually
improve activity over wild-type GTs. In addition, the crystal
structure of GtfAH1 with and without a bound UDP-2F-Glc
provides detailed information regarding the generation of
a successful chimera and is an unprecedented insight into
the way in which glycopeptide GTs bind sugars. Since the
vastmajority of GTs involved in natural product biosynthesis
belong to the same GT-B structural superfamily, GT domain
swappingmay be a general strategy for directing the biosyn-
thesis of clinically relevant natural products.
EXPERIMENTAL PROCEDURES
Chemicals
Teicoplanin was purchased from Advanced Separation Technologies Ltd.,
DNA primers were purchased from MWG Biotech, acetonitrile (HPLC grade)Chemistry & Biology 16,was purchased from Fisher Scientific, and all other chemicals were purchased
from Sigma-Aldrich and were of analytical grade. AGT was synthesized by the
acid-catalyzed degradation of teicoplanin using published procedures (Boger
et al., 2000). AGV and DVV were produced by the acid-catalyzed degradation
of vancomycin (Nagarajan et al., 1989). Vancomycin N-acetylglucosaminyl
pseudoaglycone (2) was enzymatically generated using GtfB as previously
described (Truman et al., 2008).
Plasmid Construction
The generation of pET28a(+)-based plasmids encoding GtfB and Orf10* with
N-terminal hexahistidine tags have been described elsewhere (Mulichak
et al., 2001; Li et al., 2004). Plasmids encoding GtfA and Or1 with N- and
C-terminal hexahistidine tags were constructed as follows. Briefly, the genes
were amplified from cosmid DNA (van Wageningen et al., 1998; Li et al.,
2004) using the following primers (restriction sites introduced are shown in
bold): gtfAN-for, 50- GGATGCCATATGCGCGTGTTGATTACG-30; gtfAN-rev,
50- GTTCCATAGGCTCGAGGTGGTTCAGGC-30; gtfAC-for, 50-GGATGCGCC
ATGGGCGTGTTGATTACGGG-30; gtfAC_rev, 50- CATAGGCTCGGTGTCTCG
AGGGCGGGAAC-30; orf1N-for, 50- GGATGTGCATATGCGCGTGCTGTTTTC
GTC-30; orf1N-rev, 50- GGCGGAATTCACGCGGGAACCGACGATC-30; orf1C-
for, 50- GGATGTGACCATGGGCGTGCTGTTTTCGTC-30; orf1C-rev, 50- GGCG
CAAGCTTCGCGGGAACCGACGATCTC-30.
PCR reactions were carried out using KOD Hot Start DNA polymerase
(Novagen) according to the manufacturer’s instructions. After digestion (New
England Biolabs), the products were ligated (T4 Ligase; Stratagene) into the
corresponding sites in a pET28(a)+ expression vector (Novagen). gtfB and
orf10* plasmids were doubly digested using MluI and PstI to generate linear
fragments of 1508 bp/5044 bp (Orf10*) and 1505 bp/5046 bp (GtfB). The heter-
ologous re-ligation of the small fragments with the large fragments resulted
in the generation of pET28(a)+ constructs harboring the hybrid GT genes
(1508 bp + 5046 bp = N-terminal Orf10* and C-terminal GtfB; 1505 bp +
5044 bp =N-terminal GtfB andC-terminal Orf10*). GtfA-Orf1 hybrid constructs
were generated by digesting the Orf1 and GtfA plasmids using MluI and
BamHI. The heterologous re-ligation of the small and large fragments gener-
ated pET28-based plasmids encoding hybrids with N- or C-terminal hexahis-
tidine tags. The Orf1 constructs were only partially digested with BamHI owing
to a second BamHI restriction site at nucleotide 1067 in the gene. The identity
of all plasmids was confirmed by sequencing.
General Enzyme Expression Procedure
E. coli BL21(DE3) competent cells (Novagen) containing chimeric GT plasmid
were grown in LB medium (1 liter) containing kanamycin (50 mg/mL) with
shaking at 37C until the OD600 reached approximately 0.6. Isopropyl-b-D-
thiogalactopyranoside was then added to a final concentration of 0.2 mM
and cell growth was continued with shaking at 16C for 16 hr. The cells were
then harvested by centrifugation and the resulting cell pellet was suspended
in 30 ml binding buffer (10 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, and
10% glycerol [pH 7.9]) and lysed by sonication (Vibra-Cell Sonicator; Sonics
and Materials Inc.). The resulting cell lysate was clarified by centrifugation
and hexahistidine-tagged protein was purified on a HisdBind resin column (No-
vagen) at 4C following the manufacturer’s instructions.
After elution, the protein solutionwas desalted using an Amicon Ultra centrif-
ugal filter (Millipore) and the buffer was exchanged to 50 mM Tris-HCl and
100 mM KCl (pH 8.4) for GtfBH1 and GtfBH2 and to 50 mM Tris-HCl and
100 mM KCl (pH 7.5) for GtfAH1. Where necessary, the enzyme was further
purified by gel filtration on an A¨KTA Explorer FPLC system with a HiLoad
16/60 Superdex 200 Prep Grade column. The isocratic mobile phase con-
tained 100 mM KCl and 20 mM Tris-HCl (pH 8.4).
Protein identity was confirmed by LC-ESI-MS analysis: GtfBH1 observed
mass = 44496 Da (predicted mass after loss of N-formyl-methionine =
44498 Da); GtfBH2 observed mass = 44581 Da (predicted mass after loss of
N-formyl-methionine = 44584 Da); GtfAH1-N observed mass = 42600 Da (pre-
dictedmass after loss ofN-formyl-methionine = 42601Da); GtfAH1-C observed
mass=41858Da (predictedmassafter lossofN-formyl-methionine=41859Da).
Glycopeptide LC-ESI-MS Data Acquisition
Spectra were obtained using a Hewlett-Packard HPLC 1100 series instrument
coupled to a Finnigan MAT LCQ ion trap mass spectrometer fitted with676–685, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 683
Chemistry & Biology
Chimeric Glycopeptide Glycosyltransferasesa positive mode ESI source. Samples were injected onto a Phenomenex Luna
C18(2) column (250 mm 3 2.0 mm, 5 mm), eluting with a linear gradient of 0 to
60% acetonitrile containing 0.1% trifluroacetic acid (TFA) in water (0.1% TFA)
over 30 min with a flow-rate of 0.3 mL/min.
Chimeric GT Assays
A typical glycosylation reaction involved incubating the GT (5 mM) with glyco-
peptide acceptor (50 mM–1 mM) and NDP-sugar (0.5–2 mM) in buffer (75 mM
Tris-HCl [pH7.4] or 75mMTricine [pH9]), 8mMMgCl2, 2.5mMTCEP, 1mg/mL
BSA, and 10% (v/v) DMSO at 20C–37C. Assays were quenched with an
equivalent amount acetonitrile containing 0.1% TFA and directly subjected to
LC-ESI-MS analysis. Kinetic parameters were generated by curve-fitting using
Origin 7 (OriginLab). See Supplemental Methods for additional experimental
details on kinetic analyses and competitive assays.
Crystallization and Structural Determination
The protein was crystallized using vapor diffusion by the hanging drop tech-
nique using a protein concentration of 10 mg/mL. Equal parts of crystallization
solution and protein solution were mixed forming drops of 2 mL. The crystals
were obtained in 0.1 M Tris-HCl (pH 8.5) and 1.2–2.0 M ammonium sulfate.
To facilitate data collection at 100 K, these crystals were cryoprotected using
the well solution in the presence of 30% v/v glycerol. Co-crystallization with
UDP-GlcNAc and UDP-2F-Glc was performed using concentrations of five
to ten higher than themolar concentration of the protein. X-ray data for GtfAH1
crystallized in complex with UDP were collected to 1.15 A˚ resolution at the
European Synchrotron Radiation Facility. The structure was solved by molec-
ular replacement using AMoRe (CCP4, 1994) with GtfA from A. orientalis as
a search probe (Mulichak et al., 2003). Refinement led to a final Rfactor and Rfree
of 17.1% and 18.5%, respectively. X-ray data for GtfAH1 crystallized in
complex with UDP-2F-Glc were collected to 1.30 A˚ resolution. See Table 3
for a summary of the statistics of data collection and refinement.
ACCESSION NUMBERS
Atomic coordinates for GtfAH1:UDP and GtfAH1:UDP-2F-Glc have been
deposited in the Protein Data Bank (www.rcsb.org) under the accession
numbers 3H4T and 3H4I, respectively.
SUPPLEMENTAL DATA
Supplemental Data contain nine figures and Supplemental Methods and can
be found with this article online at http://www.cell.com/chemistry-biology/
supplemental/S1074-5521(09)00178-1.
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